Having trouble accessing articles? Reset your cache.

Dificid fidaxomicin regulatory update

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said that Dificlir fidaxomicin from Astellas has "no additional benefit"

Read the full 199 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE